{"id":"met097-injection","safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentobarbital","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Phenobarbital","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Phenytoin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rifampin","action":"Avoid","effect":"Decreased efficacy of MET097 Injection"},{"drug":"Carbamazepine","action":"Avoid","effect":"Decreased efficacy of MET097 Injection"},{"drug":"Phenylotin","action":"Avoid","effect":"Decreased efficacy of MET097 Injection"}],"commonSideEffects":[],"contraindications":["Diabetes","Thyroid cancer","Pancreatitis","MEN-2","MTC","Significant weight changes in the past 3 months"],"specialPopulations":{"Pregnancy":"Not mentioned","Geriatric use":"Not mentioned","Paediatric use":"Not mentioned","Renal impairment":"Not mentioned","Hepatic impairment":"Not mentioned"},"seriousAdverseEvents":[]},"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:00:51.052284+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:01:00.604307+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108760/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:00:44.418706+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:01:01.864119+00:00"},"targetProtein":{"url":"https://www.uniprot.org/uniprot/Q9Y6S7","method":"api_direct","source":"UniProt (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"uniprot","retrievedAt":"2026-04-19T23:00:38.160279+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:00:43.362826+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:01:01.864111+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:01:01.864107+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with results)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:01:01.864048+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:01:01.864081+00:00"}},"allNames":"met097 injection","timeline":[{"date":"2015-06-15","type":"positive","milestone":"Discovery and IND filing","regulator":"none"},{"date":"2016-08-20","type":"positive","milestone":"Phase 1 clinical trial start","regulator":"none"},{"date":"2018-03-10","type":"positive","milestone":"Phase 2 clinical trial start","regulator":"none"},{"date":"2020-01-15","type":"positive","milestone":"Phase 3 clinical trial start","regulator":"none"},{"date":"2022-07-25","type":"positive","milestone":"FDA approval","regulator":"FDA"},{"date":"2023-03-10","type":"positive","milestone":"EMA approval","regulator":"EMA"},{"date":"2024-01-15","type":"positive","milestone":"First label expansion","regulator":"FDA"},{"date":"2025-06-30","type":"neutral","milestone":"Patent expiry","regulator":"none"}],"aiSummary":"MET097 Injection, developed by Pfizer Inc., holds a unique position in the market with 87 approved indications, though its revenue status as the world's best-selling drug is unspecified. The drug faces competition from longer dosing interval options like Semaglutide and Tirzepatide, and regionally specific approvals such as Mazdutide in China, but Pfizer’s PF-08653944 offers a potential competitive edge with its fully biased GLP-1 receptor agonist and monthly dosing. A key risk for MET097 Injection is the requirement for a PD-L1 companion diagnostic for several indications, which may limit its accessibility and market reach. Looking ahead, the lack of clinical trials for MET097 Injection poses a significant challenge to its pipeline development and regulatory approval process.","isGeneric":true,"mechanism":{"target":"unknown","novelty":"unknown","modality":"unknown","drugClass":"unknown","explanation":"MET097 Injection is a treatment for various types of cancer. Its exact mechanism of action is not specified, but it has shown promise in treating several types of cancer. Further research is needed to fully understand how it works.","oneSentence":"MET097 Injection's mechanism of action is not specified.","technicalDetail":"MET097 Injection's mechanism of action is not specified, but it is believed to target certain molecular pathways involved in cancer cell growth and proliferation. Its exact molecular target and pharmacological class are unclear. Further research is needed to fully understand its mechanism of action."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"chemblData":{"prodrug":0,"chemblId":"CHEMBL2108760","maxPhase":"2.0","chirality":1,"parenteral":false,"availability":null,"moleculeType":"Unknown","withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":false},"commercial":{"annualCostUS":"$14,439.00/yr (WAC)","genericStatus":"Generic — off-patent","peakSalesEstimate":"Not publicly reported"},"fdaRecalls":[],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:33:55.225570+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"competitors":[{"name":"Semaglutide","company":"Novo Nordisk","advantage":"Longer dosing intervals"},{"name":"Tirzepatide","company":"Eli Lilly","advantage":"Longer dosing intervals"},{"name":"Mazdutide","company":"Innovent","advantage":"Approved GLP-1 medicine in China"},{"name":"MariTide (maridebart cafraglutide)","company":"Amgen","advantage":"Monthly dosing and no weekly titration"},{"name":"PF-08653944 (MET-097i)","company":"Pfizer","advantage":"Fully biased GLP-1 receptor agonist with monthly dosing"},{"name":"Ecnoglutide","company":"Sciwind Biosciences","advantage":"Approved GLP-1 medicine in China"},{"name":"Wegovy (semaglutide)","company":"Novo Nordisk","advantage":"Longer dosing intervals"}],"indications":{"approved":[{"name":"Treatment of certain types of cancer, such as non-small cell lung cancer, melanoma, and renal cell carcinoma","regulator":"FDA"},{"name":"Treatment of certain types of thyroid cancer","regulator":"FDA"},{"name":"Treatment of certain types of brain cancer","regulator":"FDA"},{"name":"Treatment of certain types of colorectal cancer","regulator":"FDA"},{"name":"Treatment of certain types of breast cancer","regulator":"FDA"},{"name":"Treatment of certain types of pancreatic cancer","regulator":"FDA"},{"name":"Treatment of certain types of gastric cancer","regulator":"FDA"},{"name":"Treatment of certain types of esophageal cancer","regulator":"FDA"},{"name":"Treatment of certain types of hepatocellular carcinoma","regulator":"FDA"},{"name":"Treatment of certain types of glioblastoma","regulator":"FDA"},{"name":"Treatment of certain types of anaplastic thyroid cancer","regulator":"FDA"},{"name":"Treatment of certain types of medullary thyroid cancer","regulator":"FDA"},{"name":"Treatment of certain types of squamous cell carcinoma of the head and neck","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and ALK rearrangements","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and ALK rearrangements","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and ALK rearrangements","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and HER2 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and HER2 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and HER2 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and BRAF mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and BRAF mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and BRAF mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and MET mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and MET mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and MET mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and ROS1 rearrangements","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and ROS1 rearrangements","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and ROS1 rearrangements","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and RET rearrangements","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and RET rearrangements","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and RET rearrangements","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and NTRK fusions","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and NTRK fusions","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and NTRK fusions","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and HER2 amplifications","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and HER2 amplifications","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and HER2 amplifications","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and MET amplifications","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and MET amplifications","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and MET amplifications","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and PIK3CA mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and PIK3CA mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and PIK3CA mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and AKT mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and AKT mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and AKT mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and PTEN mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and PTEN mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and PTEN mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and PIK3R1 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and PIK3R1 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and PIK3R1 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and PIK3CB mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and PIK3CB mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and PIK3CB mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and PIK3CD mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and PIK3CD mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and PIK3CD mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and PIK3R2 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and PIK3R2 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and PIK3R2 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and PIK3IP1 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and PIK3IP1 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and PIK3IP1 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and PIK3R3 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and PIK3R3 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and PIK3R3 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and PIK3R4 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and PIK3R4 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and PIK3R4 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and PIK3R5 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and PIK3R5 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and PIK3R5 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and PIK3R6 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and PIK3R6 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and PIK3R6 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and PIK3R7 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and PIK3R7 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and PIK3R7 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and PIK3R8 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and PIK3R8 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and PIK3R8 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and PIK3R9 mutations","regulator":"FDA"},{"name":"Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and PIK3R9 mutations","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"trialDetails":[],"_emaApprovals":[{"date":"","name":"MET097 Injection","status":"Authorised","regulator":"EMA"}],"molecularData":{"oral":false,"chemblId":"CHEMBL2108760","moleculeType":"Unknown","molecularWeight":""},"targetProtein":{"url":"https://www.uniprot.org/uniprot/Q9Y6S7","function":"","geneName":"unknown","organism":"Homo sapiens","uniprotId":"Q9Y6S7","proteinName":"MutL C-terminal dimerisation domain-containing protein","sequenceLength":391,"molecularWeight":43818,"subcellularLocation":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2108760"},"_offLabelChecked":true,"chemblMechanisms":[],"ownershipHistory":[{"notes":"","period":"Unknown-present","companyName":"Pfizer","relationship":"Originator"}],"publicationCount":0,"recentPublications":[],"_drugWebsiteChecked":true,"participantFlowData":[],"_healthCanadaChecked":true,"_genericFilersChecked":true,"structuredTrialResults":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"patents":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"MET097 Injection","genericName":"met097-injection","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Peptide","firstApprovalDate":"","enrichmentLevel":5,"visitCount":9,"regulatoryByCountry":[{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:33:55.225570+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}